APA (7th ed.) Citation

Heumann, T. R., Baretti, M., Sugar, E. A., Durham, J. N., Linden, S., Lopez-Vidal, T. Y., . . . Azad, N. S. (2022). A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Clinical Epigenetics, 14(1), . https://doi.org/10.1186/s13148-022-01367-8

Chicago Style (17th ed.) Citation

Heumann, Thatcher R., et al. "A Randomized, Phase II Trial of Oral Azacitidine (CC-486) in Patients with Resected Pancreatic Adenocarcinoma at High Risk for Recurrence." Clinical Epigenetics 14, no. 1 (2022). https://doi.org/10.1186/s13148-022-01367-8.

MLA (9th ed.) Citation

Heumann, Thatcher R., et al. "A Randomized, Phase II Trial of Oral Azacitidine (CC-486) in Patients with Resected Pancreatic Adenocarcinoma at High Risk for Recurrence." Clinical Epigenetics, vol. 14, no. 1, 2022, https://doi.org/10.1186/s13148-022-01367-8.